CJC-1295

Intro

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic signal that triggers pituitary GH secretion.

It exists in two pharmacologically distinct variants that are frequently confused: CJC-1295 with DAC (Drug Affinity Complex), which has a half-life of 6-8 days via covalent albumin binding, and CJC-1295 without DAC — also called Mod GRF 1-29 or Modified GRF 1-29 — which has a half-life of approximately 30 minutes. The naming overlap is a persistent source of community confusion.

The DAC variant is the form studied in the only human clinical trial (Teichman et al. 2006, PMID 16352683), a randomized placebo-controlled ascending-dose study in healthy adults ages 21-61. A single subcutaneous injection produced dose-dependent GH elevation of 2-10x sustained for 6+ days and IGF-1 elevation of 1.5-3x sustained for 9-11 days. With multiple doses, IGF-1 remained above baseline for up to 28 days. The estimated pharmacokinetic half-life was 5.8-8.1 days. No serious adverse reactions were reported.

CJC-1295 is almost never used alone. It forms the GHRH component of the most widely used injectable GH secretagogue protocol, combined with a ghrelin receptor agonist (typically ipamorelin) to activate two distinct GH-release pathways simultaneously. The combination produces synergistic GH pulses exceeding either compound alone. Results are gradual: sleep quality improvement emerges in weeks 1-2, body composition changes develop over 8-16 weeks. This is a recomposition tool operating over months, not a weight-loss agent comparable to GLP-1 agonists.

Observed Effects

Body recomposition is the primary objective for most users — concurrent fat loss and lean mass gain over 8-16 weeks.

Visceral fat responds disproportionately well to GH elevation. Clinical-adjacent estimates place realistic outcomes at 4-8 kg fat loss and 2-4 kg lean mass gain over a 3-6 month cycle with adequate diet and resistance training. DEXA-confirmed community data supports this range: one 8-month user documented concurrent fat loss and muscle gain in the first cycle. Results across cycles were inconsistent, underscoring the importance of training and nutrition as co-factors. The stack does not produce GLP-1-class acute weight reduction.

Sleep quality improvement is the most consistently reported early effect, emerging in weeks 1-2 across multiple independent user logs. Users describe deeper sleep, more vivid dreams, and waking feeling restored — consistent with GH's coupling to slow-wave sleep architecture. Joint and tendon improvements are reported by some users after several weeks, including reduced morning achiness and improved tissue resilience during high-demand physical work.

IGF-1 elevation is the objective biomarker of efficacy. One community user running CJC-1295 DAC 5 mg/week combined with MK-677 documented IGF-1 rising from ~179 to 322 ng/mL. CJC-1295 DAC combined with MK-677 can drive IGF-1 into ranges comparable to high-dose pharmaceutical GH. Gym-specific observations include improved training pumps, better session-to-session recovery, and enhanced tissue fullness — described as qualitatively distinct from exogenous pharmaceutical GH, which produces more pronounced cosmetic and 'dryness' effects.

Secondary libido and mood improvements are reported by some users after 4-6 weeks; these likely reflect improved sleep quality and general GH-axis normalization rather than direct androgenic activity — CJC-1295 has no androgenic properties.

Field Reports

Independent long-term user accounts provide texture that GH/IGF-1 biomarker data from clinical trials cannot. The most detailed accounts come from users running 3-8 month logs with body scans and some bloodwork.

Sleep improvement is the first and most consistent signal — users across multiple independent logs describe deeper, more restful sleep within the first 2-3 weeks. This is mechanistically grounded: GH is primarily secreted during the first slow-wave sleep cycle, and amplifying the nocturnal GHRH signal directly enhances sleep architecture quality.

Body composition changes develop slowly. DEXA-confirmed results in one 8-month log spanning three cycles showed fat loss and simultaneous muscle gain in the first cycle — concurrent recomposition that is difficult to achieve without hormonal support. However, the second cycle showed the reverse under different conditions, demonstrating that diet and training context dominates outcomes. The peptides create a favorable hormonal environment; the user must supply the training stimulus.

Injection site reactions are common and variable across cycles, potentially reflecting product quality differences, immune sensitization with repeated exposure, or both. One user developed escalating allergic-type reactions by the third cycle requiring dose reduction and physician consultation.

The community's comparison of GH secretagogues to exogenous pharmaceutical GH is consistently honest: peptide-based GH stimulation does not replicate the cosmetic 'dry, hard' effect associated with high-dose pharmaceutical GH. The subjective experience is described as enhanced recovery, better sleep, improved training pumps, and gradual recomposition — qualitatively distinct from high-dose exogenous GH.

Community Consensus

CJC-1295 occupies the GHRH half of the standard injectable GH secretagogue pattern. The pairing with ipamorelin is deeply embedded in community practice because it combines a GHRH signal with a ghrelin-receptor signal without using MK-677's continuous appetite and glucose burden. Community discourse centers on three persistent themes: the DAC vs no-DAC naming confusion, the non-negotiable fasted injection requirement, and managing expectations about the timeline and magnitude of results.

The community has converged on result expectations that align with clinical-adjacent estimates: sleep improvement in weeks 1-2, body composition changes visible at 8-16 weeks, and a 3-6 month commitment for meaningful fat loss and lean mass changes. The comparison to GLP-1 agonists is explicitly rejected across community sources — this is a recomposition tool with a gradual timeline, not an acute weight-loss drug. This represents a significant improvement in community expectations compared to the earlier era where CJC-1295 was marketed with exaggerated outcomes.

Practitioners with experience across the secretagogue class suggest that CJC-1295 and comparable GHRH analogs produce qualitatively similar outcomes when used in equivalent protocols — the mechanistic distinctions are real but the practical differences in outcome are modest. Individual compound differentiation in this class is often driven more by study availability and marketing than by meaningfully distinct real-world effects.

The DAC form is preferred in clinical and travel contexts for its once-weekly dosing convenience. The no-DAC form is preferred in body composition protocols for its pulsatility and stacking flexibility with ipamorelin. CJC-1295 plus MK-677 appears in advanced growth-phase discussion, but it should not be treated as the normal base stack because both compounds push the same IGF-1/glucose/edema lane. Discussion about whether sustained GHRH stimulation from DAC causes pituitary desensitization remains ongoing — this concern is theoretical and not confirmed in available clinical data through 49 days.

Risks & Monitoring

Injection site reactions are common and vary across cycles: warmth, mild redness, or mosquito-bite-like welts at the injection site.

A transient head-rush or flush sensation within 3-5 minutes of injection is frequently reported early in treatment and diminishes with continued use as the body adapts.

Mild water retention in the first 1-2 weeks is typical, particularly with the DAC form or when stacked with MK-677. It commonly manifests as ankle and facial puffiness that resolves with sodium management. At elevated GH/IGF-1 levels, carpal tunnel-like tingling (hand numbness at night) can occur, attributed to water retention increasing pressure on wrist nerves — a known GH-class effect that is dose-dependent.

One long-term user developed escalating allergic-type injection reactions by the third cycle (generalized itching migrating to different body parts nightly), requiring dose reduction to half and physician consultation. This pattern suggests immune sensitization with repeated exposure or batch-specific reactivity.

Theoretical concerns that are mechanistically plausible but not clinically confirmed include pituitary desensitization from sustained non-pulsatile GHRH stimulation (relevant primarily to the DAC form over long cycles) and serum protein changes — CJC-1295 was shown to downregulate apolipoprotein A1 and transthyretin isoforms and upregulate beta-hemoglobin and albumin fragments (Sackmann-Sala 2009, n=11 healthy men); clinical significance is unknown.

GH elevation and cancer: GH promotes cellular proliferation and may theoretically feed pre-existing cancer cells. CJC-1295 does not initiate cancer, but use in oncology patients is contraindicated. If you do not have active cancer, this is not an acute risk.

The Teichman 2006 RCT reported no serious adverse reactions at any dose tested. Community data do not document serious adverse events beyond the injection site and GH-class effects described above.

For Women

Monitoring Panels

Avoid With

Protocols By Goal

Body recomposition: CJC-1295 no-DAC 300 mcg plus ipamorelin 300 mcg before bed, 5 days on/2 days off.

Cycle 12-16 weeks. Monitor IGF-1 at baseline and week 8. Support with resistance training and protein intake of 1.6-2.2 g/kg/day. Allow 8-16 weeks for meaningful body composition changes.

Anti-aging and longevity: CJC-1295 DAC 2 mg twice weekly for simplified adherence. Monitor IGF-1 twice yearly. Target upper quartile of age-matched IGF-1 reference range as a proxy endpoint for GH axis optimization.

Recovery and injury repair: CJC-1295 no-DAC 200-300 mcg plus ipamorelin 200-300 mcg before bed. Collagen synthesis and tissue repair benefit from sustained GH/IGF-1 elevation over 8-12 weeks. Often combined with BPC-157 for complementary local healing effects alongside systemic GH elevation.

GH axis optimization over 40: Preferred first step for age-related GH decline before considering exogenous GH. Users in their 30s-40s respond more strongly to secretagogues than those in their 50s-70s, whose enzymatic GH-releasing capacity has declined. Start with no-DAC plus ipamorelin before evaluating whether response justifies advancing to exogenous GH.

Fat loss with fasted cardio: Before fasted morning cardio, add CJC-1295 no-DAC 100-200 mcg plus ipamorelin 100-200 mcg as a supplementary injection. Each secretagogue contributes modestly to lipolytic conditions during fasted exercise. This is additive rather than transformative; the bedtime dose remains the foundation of the protocol.

Dosing Details

CJC-1295 exists in two variants with fundamentally different dosing patterns.

CJC-1295 no-DAC (Mod GRF 1-29) + Ipamorelin stack: The standard community pattern combines 100-300 mcg CJC-1295 no-DAC with 100-300 mcg ipamorelin per administration, with 300/300 mcg common in community protocols. Frequency is usually 1-3 times daily, with bedtime as the baseline timing and pre-workout or pre-fasted-cardio additions in some protocols. Fasted use is emphasized because glucose and insulin blunt GH pulses. Many community protocols use 5 days on/2 days off per week to reduce potential GHS-R1a receptor desensitization from continuous daily ipamorelin exposure.

CJC-1295 DAC standalone: Community DAC patterns commonly use 1-2 mg once or twice weekly, with 2 mg twice weekly (4 mg/week total) described as a high-adherence protocol and 1 mg twice weekly as a conservative starting pattern. Steady state is reached after 2-3 injections (approximately 10-14 days). DAC is preferred for travel and high-adherence scenarios. DAC plus MK-677 should not be treated as a routine escalation because both push the GH/IGF-1 axis and compound the same glucose, edema, appetite, and water-retention burdens.

Clinical reference: The Teichman 2006 trial used doses of 30-60 mcg/kg for best tolerability — approximately 2.4-4.8 mg for an 80 kg adult. Community no-DAC daily doses of 100-300 mcg are substantially below the clinical single-dose range. Community DAC doses of 2-4 mg weekly are within the clinical trial range.

Handling context: Research-peptide use adds sterility, dilution, storage, variant-identification, and route logistics. Those mechanics are operational risk and should not be improvised from article prose.

Stacks & Alternatives

The canonical pairing. Ipamorelin activates the ghrelin receptor (GHS-R1a) while CJC-1295 activates the GHRH receptor — dual-pathway stimulation produces synergistic GH pulses exceeding either compound alone. Ipamorelin's selectivity — no cortisol, prolactin, or aldosterone elevation — makes it the preferred GHRP for this combination.

Oral ghrelin mimetic that overlaps heavily with the same GH/IGF-1 goal as CJC-1295 and ipamorelin. It is better framed as an injection-averse substitute or an advanced growth-phase add-on, not a routine third member of the CJC/ipamorelin base.

GH C-terminal fragment with selective lipolytic activity and no IGF-1-elevating effect. Adding 100-200 mcg before fasted cardio provides a fat oxidation signal without pushing IGF-1 higher in users already achieving target levels on CJC-1295.

Complementary healing peptide. CJC-1295 provides systemic GH/IGF-1 elevation supporting tissue repair; BPC-157 acts locally at injury sites through distinct pathways including angiogenesis and nitric oxide signaling. The combination addresses healing from both systemic and local angles.

Advanced layering: secretagogues can be administered 60-90 minutes before an exogenous GH injection to prime the GH release system enzymatically and provide additional receptor-level stimulation. Used in competitive performance contexts.

Alternatives

Stack Cost

Practical Setup

Fasted administration is the single most emphasized protocol detail. GH secretion is inversely related to blood glucose and insulin, so eating close to CJC-1295 plus ipamorelin can blunt the GH pulse.

For users on GLP-1 agonists, community protocols usually extend the fasting window. Bedtime use is the natural implementation for many users.

The 5 days on/2 days off weekly pattern is widely used to provide GHS-R1a receptor recovery from continuous daily ghrelin-receptor stimulation. There is no clinical evidence establishing whether this matters; it is a harm-reduction convention that adds minimal inconvenience and is broadly adopted.

Results take time. Users who assess at 4 weeks and see no dramatic change are following a common pattern. Meaningful changes accumulate at 8-16 weeks. The most accessible early indicator is sleep quality, which should be noticeably better within 2-3 weeks if the peptides are genuine and the protocol is correctly timed.

Peptide authenticity matters significantly in the research compound market. Some users report a transient head-rush within minutes as a weak functional quality signal from ghrelin-receptor activation, but subjective sensation is not reliable. Third-party testing or bloodwork confirmation of IGF-1 elevation are the only strong verification methods.

Age affects response. Users in their 30s-40s respond more strongly to secretagogues than those in their 50s-70s, likely because enzymatic GH-release capacity declines with age. Older users may require higher exposure for equivalent IGF-1 response or may respond better to exogenous GH.

Water retention in the first 1-2 weeks is common, particularly with the DAC form or when stacked with MK-677. Persistent or severe edema is a dose-reduction and medical-review signal.

Mechanism Deep Dive

CJC-1295 mimics growth hormone-releasing hormone (GHRH), the hypothalamic signal that triggers pituitary GH secretion.

GHRH is released in pulses entrained to blood glucose levels (rising when glucose falls), slow-wave sleep architecture, and alpha-2 adrenergic tone. It binds to the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, activating Gs-coupled adenylyl cyclase, raising intracellular cAMP, and activating PKA — priming the somatotroph for GH synthesis and vesicular release.

Native GHRH (44 amino acids) has a circulating half-life of approximately 7 minutes due to rapid DPP-4 cleavage at the N-terminal alanine-serine bond at position 2. The GHRH 1-29 fragment retains full biological activity but shares this short half-life. CJC-1295 is a modified GHRH 1-29 with four amino acid substitutions at positions 2, 8, 15, and 27 that resist DPP-4 degradation, extending half-life to approximately 30 minutes (no-DAC form).

The DAC modification adds an N-epsilon-3-maleimidopropionamide derivative of lysine at the C-terminus. After subcutaneous injection, the reactive maleimide undergoes a spontaneous Michael addition reaction with the free thiol of Cys34 on serum albumin — the only freely accessible cysteine on circulating albumin. This thioether bond is essentially irreversible. The resulting approximately 72 kDa albumin-CJC-1295 conjugate shares albumin's 19-day plasma half-life and is protected from both DPP-4 cleavage (sterically blocked by albumin) and renal filtration (the 72 kDa conjugate far exceeds the glomerular filtration threshold of approximately 30 kDa). Effective CJC-1295 DAC half-life in humans: 5.8-8.1 days.

A key mechanistic insight: CJC-1295 does not amplify GH pulse amplitude or frequency — it elevates basal trough GH levels between pulses. Pulsatile GH release remains intact because endogenous somatostatin continues to periodically gate GH release even during sustained GHRH receptor activation. This somatostatin gating explains why CJC-1295 DAC produces elevated continuous GH rather than a flat infusion, and why elevated trough GH — not peak pulse amplitude — is the primary driver of sustained IGF-1 production. This also explains the synergy with GHRPs like ipamorelin: GHRP compounds add pulse amplitude while CJC-1295 raises the baseline between pulses.

Downstream, GH elevation triggers hepatic IGF-1 production through JAK-STAT signaling in hepatocytes. IGF-1 is the primary effector for most anabolic and lipolytic GH effects. In adipose tissue, GH directly promotes lipolysis by activating hormone-sensitive lipase and promoting free fatty acid release. Visceral adipose tissue has higher GH receptor density than subcutaneous fat, explaining its preferential response to GH elevation.

Evidence Index